Johnson & Johnson has entered into an agreement to acquire V-Wave, a company developing treatment modalities for patients with heart failure.
Through this strategic move, Johnson & Johnson will acquire V-Wave for USD $600m upfront, with the potential for additional regulatory and commercial milestone payments totalling $1.1bn.
V-Wave will join the company as part of Johnson & Johnson MedTech.
Through the acquisition Johnson & Johnson plans to accelerate its movement into high-growth and opportunity markets, while also forming relationships with cardiologists and specialists in heart failure.
V-Wave currently has a range of products to support patients with heart failure, including cardiovascular implant technology for heart failure with reduced ejection fraction (HFrEF), as well as the Ventura Interatrial Shunt (IAS) to decrease elevated left atrial pressure seen in congestive heart failure.
Ventura received FDA Breakthrough Device Designation in 2019 and CE mark in 2020 and — if approved — could be the first device of its kind on the market.
Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, Tim Schmid, commented, “We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease. We recognise the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs."
"We know V-Wave well, with our relationship dating back to our original investment in the company in 2016, and we have a deep understanding of the technology and science, as well as the company’s commitment to patients.”
“At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission,” said V-Wave's CEO, Dr Neal Eigler. “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible. I couldn’t be prouder of the V-Wave team, and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured.”
